Related Experiment Video
Updated: May 1, 2026
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Role of methylglyoxal in Alzheimer's disease
Cristina Angeloni1, Laura Zambonin2, Silvana Hrelia1
1Department for Life Quality Studies, Alma Mater Studiorum, University of Bologna, Corso d'Augusto 237, 47900 Rimini, Italy.
Abstract:
Alzheimer's disease is the most common and lethal neurodegenerative disorder. The major hallmarks of Alzheimer's disease are extracellular aggregation of amyloid β peptides and, the presence of intracellular neurofibrillary tangles formed by precipitation/aggregation of hyperphosphorylated tau protein. The etiology of Alzheimer's disease is multifactorial and a full understanding of its pathogenesis remains elusive. Some years ago, it has been suggested that glycation may contribute to both extensive protein cross-linking and oxidative stress in Alzheimer's disease. Glycation is an endogenous process that leads to the production of a class of compounds known as advanced glycation end products (AGEs). Interestingly, increased levels of AGEs have been observed in brains of Alzheimer's disease patients. Methylglyoxal, a reactive intermediate of cellular metabolism, is the most potent precursor of AGEs and is strictly correlated with an increase of oxidative stress in Alzheimer's disease. Many studies are showing that methylglyoxal and methylglyoxal-derived AGEs play a key role in the etiopathogenesis of Alzheimer's disease.
Insights
Glycation contributes to Alzheimer's disease (AD) pathogenesis through advanced glycation end products (AGEs). Methylglyoxal, a key AGE precursor, increases oxidative stress, exacerbating AD progression.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alzheimer's disease (AD) is a leading neurodegenerative disorder characterized by amyloid-beta plaques and tau tangles.
- The complex etiology of AD necessitates exploring additional contributing factors beyond traditional hallmarks.
- Glycation, an endogenous process, has emerged as a potential player in AD pathogenesis.
Purpose of the Study:
- To investigate the role of glycation and advanced glycation end products (AGEs) in Alzheimer's disease.
- To examine the contribution of methylglyoxal (MGO) as a precursor to AGEs and its link to oxidative stress in AD.
Main Methods:
- Review of existing literature on glycation, AGEs, MGO, and oxidative stress in the context of Alzheimer's disease.
- Analysis of studies reporting increased AGE levels in AD brains.
Main Results:
- Elevated levels of AGEs are consistently observed in the brains of Alzheimer's disease patients.
- Methylglyoxal (MGO), a potent AGE precursor, is strongly correlated with increased oxidative stress in AD.
- MGO and its derived AGEs are implicated in the underlying mechanisms of Alzheimer's disease.
Conclusions:
- Glycation significantly contributes to Alzheimer's disease pathology via AGE formation.
- Methylglyoxal-induced AGEs and oxidative stress are key factors in Alzheimer's disease etiopathogenesis.
- Targeting glycation pathways may offer novel therapeutic strategies for Alzheimer's disease.
More Related Videos
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
06:26Analyzing the Permeability of the Blood-Brain Barrier by Microbial Traversal through Microvascular Endothelial Cells
Published on: February 14, 2020
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:29Alzheimer Disease l: Introduction
01:22Alzheimer's Disease: Treatment
01:23Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...